178 related articles for article (PubMed ID: 30818375)
1. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
[TBL] [Abstract][Full Text] [Related]
2. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases.
Young LR; Vandyke R; Gulleman PM; Inoue Y; Brown KK; Schmidt LS; Linehan WM; Hajjar F; Kinder BW; Trapnell BC; Bissler JJ; Franz DN; McCormack FX
Chest; 2010 Sep; 138(3):674-81. PubMed ID: 20382711
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
[TBL] [Abstract][Full Text] [Related]
4. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
[TBL] [Abstract][Full Text] [Related]
5. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM).
Xu KF; Zhang P; Tian X; Ma A; Li X; Zhou J; Zeng N; Gui YS; Guo Z; Feng R; Zhang W; Sun W; Cai B
Respir Med; 2013 Feb; 107(2):263-8. PubMed ID: 23127572
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y
Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
[TBL] [Abstract][Full Text] [Related]
9. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
Radzikowska E; Jaguś P; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
Respir Med; 2015 Nov; 109(11):1469-75. PubMed ID: 26386638
[TBL] [Abstract][Full Text] [Related]
10. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
Glasgow CG; Avila NA; Lin JP; Stylianou MP; Moss J
Chest; 2009 May; 135(5):1293-1300. PubMed ID: 19420197
[TBL] [Abstract][Full Text] [Related]
11. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
[TBL] [Abstract][Full Text] [Related]
12. The role of moesin in diagnosing and assessing severity of lymphangioleiomyomatosis.
Song X; Cai H; Peng W; Chen K; Abuduxukuer Z; Zeng Y; Zhu G; Lu C; Chen Y; Wang J; Ye L; Jin M
Respir Res; 2024 Jan; 25(1):57. PubMed ID: 38267973
[TBL] [Abstract][Full Text] [Related]
13. Role of serum vascular endothelial growth factor D in discrimination of patients with polycystic lung diseases.
Radzikowska E; Jaguś P; Skoczylas A; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
Pol Arch Med Wewn; 2013; 123(10):533-8. PubMed ID: 24060688
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.
Chang WY; Cane JL; Blakey JD; Kumaran M; Pointon KS; Johnson SR
Respir Res; 2012 Apr; 13(1):34. PubMed ID: 22513045
[TBL] [Abstract][Full Text] [Related]
16. Emerging biomarkers of lymphangioleiomyomatosis.
Nijmeh J; El-Chemaly S; Henske EP
Expert Rev Respir Med; 2018 Feb; 12(2):95-102. PubMed ID: 29171770
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
[TBL] [Abstract][Full Text] [Related]
18. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
Xu W; Yang C; Cheng C; Wang Y; Hu D; Huang J; He Y; Wang J; Chen K; Yang L; Zhou W; Zhang T; Liu S; Dai J; Meng S; Li X; Yang Y; Wang ST; Feng R; Zhang W; Zhang H; Wang L; Tian X; Xu KF
Chest; 2023 Jul; 164(1):137-148. PubMed ID: 36801466
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
